CA2962254A1 - Composition et procede de traitement de l'adn - Google Patents
Composition et procede de traitement de l'adn Download PDFInfo
- Publication number
- CA2962254A1 CA2962254A1 CA2962254A CA2962254A CA2962254A1 CA 2962254 A1 CA2962254 A1 CA 2962254A1 CA 2962254 A CA2962254 A CA 2962254A CA 2962254 A CA2962254 A CA 2962254A CA 2962254 A1 CA2962254 A1 CA 2962254A1
- Authority
- CA
- Canada
- Prior art keywords
- dna
- enzyme
- trigger
- uracil
- duplex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 72
- 239000000203 mixture Substances 0.000 title claims description 19
- 238000012545 processing Methods 0.000 title claims description 15
- 239000012634 fragment Substances 0.000 claims abstract description 64
- 108020004414 DNA Proteins 0.000 claims description 150
- 102000004190 Enzymes Human genes 0.000 claims description 66
- 108090000790 Enzymes Proteins 0.000 claims description 66
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 64
- 125000003729 nucleotide group Chemical group 0.000 claims description 60
- 239000002773 nucleotide Substances 0.000 claims description 48
- 229940035893 uracil Drugs 0.000 claims description 32
- 102000053602 DNA Human genes 0.000 claims description 21
- 108010036364 Deoxyribonuclease IV (Phage T4-Induced) Proteins 0.000 claims description 19
- 238000003752 polymerase chain reaction Methods 0.000 claims description 19
- 239000002243 precursor Substances 0.000 claims description 14
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 13
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 claims description 11
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 10
- 239000013067 intermediate product Substances 0.000 claims description 9
- 208000035657 Abasia Diseases 0.000 claims description 8
- 230000036961 partial effect Effects 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 claims description 7
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 5
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 5
- 108020001019 DNA Primers Proteins 0.000 claims description 4
- 239000003155 DNA primer Substances 0.000 claims description 4
- 125000002680 canonical nucleotide group Chemical group 0.000 claims description 4
- 102100031780 Endonuclease Human genes 0.000 claims description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 238000010804 cDNA synthesis Methods 0.000 description 34
- 239000002299 complementary DNA Substances 0.000 description 34
- 108020004635 Complementary DNA Proteins 0.000 description 31
- 238000003776 cleavage reaction Methods 0.000 description 30
- 230000007017 scission Effects 0.000 description 30
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 14
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 13
- 238000012165 high-throughput sequencing Methods 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000013615 primer Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 108010002082 endometriosis protein-1 Proteins 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 239000011324 bead Substances 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 101710180995 Endonuclease 1 Proteins 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3-methyladenine Chemical compound CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 3
- 108010082610 Deoxyribonuclease (Pyrimidine Dimer) Proteins 0.000 description 3
- 102100037696 Endonuclease V Human genes 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- 108020004703 Cruciform DNA Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- OGVOXGPIHFKUGM-UHFFFAOYSA-N 3H-imidazo[2,1-i]purine Chemical compound C12=NC=CN2C=NC2=C1NC=N2 OGVOXGPIHFKUGM-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 108091064358 Holliday junction Proteins 0.000 description 1
- 102000039011 Holliday junction Human genes 0.000 description 1
- 101100439100 Homo sapiens CEBPA gene Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- -1 rRNA Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method of cleaving DNA molecules into smaller fragments by the creation of "cleavage trigger sites" followed by enzymatic processing. ln some embodiments the "cleavage trigger sites" are created by the incorporation of nucleotides having uracil bases into a DNA molecule and processing with uracil DNA glycosylase, endonuclease IV and T7 endonuclease I.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/092,917 | 2016-04-07 | ||
| US15/092,917 US10160987B2 (en) | 2016-04-07 | 2016-04-07 | Composition and method for processing DNA |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2962254A1 true CA2962254A1 (fr) | 2017-10-07 |
| CA2962254C CA2962254C (fr) | 2020-07-28 |
Family
ID=59997561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2962254A Active CA2962254C (fr) | 2016-04-07 | 2017-03-24 | Composition et procede de traitement de l'adn |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US10160987B2 (fr) |
| CA (1) | CA2962254C (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109666745B (zh) * | 2019-02-15 | 2024-04-05 | 阅尔基因技术（苏州）有限公司 | 染色体1p/19q联合杂合性缺失的检测方法及试剂盒 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5035996A (en) | 1989-06-01 | 1991-07-30 | Life Technologies, Inc. | Process for controlling contamination of nucleic acid amplification reactions |
| US5229283A (en) | 1991-06-14 | 1993-07-20 | Life Technologies, Inc. | Use of exo-sample nucleotides in gene cloning |
| US6190865B1 (en) * | 1995-09-27 | 2001-02-20 | Epicentre Technologies Corporation | Method for characterizing nucleic acid molecules |
| US6197557B1 (en) | 1997-03-05 | 2001-03-06 | The Regents Of The University Of Michigan | Compositions and methods for analysis of nucleic acids |
| US6090553A (en) | 1997-10-29 | 2000-07-18 | Beckman Coulter, Inc. | Use of uracil-DNA glycosylase in genetic analysis |
| US6046039A (en) | 1998-08-19 | 2000-04-04 | Battelle Memorial Institute | Methods for producing partially digested restriction DNA fragments and for producing a partially modified PCR product |
| IE20000887A1 (en) | 2000-11-03 | 2002-12-11 | Univ College Cork Nat Univ Ie | Method for the amplification and optional characterisation of nucleic acids |
| US20040086890A1 (en) * | 2002-10-25 | 2004-05-06 | Stratagene | DNA polymerases with reduced base analog detection activity |
| US7851192B2 (en) | 2004-11-22 | 2010-12-14 | New England Biolabs, Inc. | Modified DNA cleavage enzymes and methods for use |
| US20060063189A1 (en) | 2004-09-21 | 2006-03-23 | Applera Corporation Applied Biosystems Group | Methods of using sulfur nucleophiles as improved alternatives to sodium bisulfite for methylated DNA analysis |
| US7658288B2 (en) | 2004-11-08 | 2010-02-09 | Applied Biosystems, Llc | Bisulfite conversion reagent |
| CA2596496A1 (fr) | 2005-02-01 | 2006-08-10 | Agencourt Bioscience Corp. | Reactifs, methodes et bibliotheques pour sequencage fonde sur des billes |
| JP5033806B2 (ja) | 2005-10-20 | 2012-09-26 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 改良された増幅のための核酸の修復 |
| US7754429B2 (en) | 2006-10-06 | 2010-07-13 | Illumina Cambridge Limited | Method for pair-wise sequencing a plurity of target polynucleotides |
| US8592150B2 (en) | 2007-12-05 | 2013-11-26 | Complete Genomics, Inc. | Methods and compositions for long fragment read sequencing |
| US8058414B2 (en) | 2008-04-29 | 2011-11-15 | Life Technologies Corporation | Unnatural polymerase substrates that can sustain enzymatic synthesis of double stranded nucleic acids from a nucleic acid template and methods of use |
| EP2393940B1 (fr) | 2009-02-03 | 2014-12-17 | New England Biolabs, Inc. | Génération de ruptures aléatoires double brin dans de l'adn à l'aide d'enzymes |
| WO2010111674A2 (fr) | 2009-03-27 | 2010-09-30 | Life Technologies Corporation | Procédés et appareil de séquençage de molécules uniques utilisant la détection par transfert d'énergie |
| DK3037536T3 (da) | 2011-01-28 | 2020-01-13 | Illumina Inc | Oligonukleotiderstatning for di-taggede og retnings biblioteker |
| WO2013040008A1 (fr) | 2011-09-12 | 2013-03-21 | University Of Notre Dame Du Lac | Systèmes et procédés permettant de détecter des nucléotides sans utiliser de billes |
| US9957558B2 (en) | 2011-04-28 | 2018-05-01 | Life Technologies Corporation | Methods and compositions for multiplex PCR |
| WO2014105246A2 (fr) | 2012-10-05 | 2014-07-03 | Massachusetts Institute Of Technology | Système de tri nano-fluidique pour la synthèse de gène et produits de réaction de pcr |
| TW201531569A (zh) * | 2014-02-12 | 2015-08-16 | Taiwan Sugar Corp | 雙股核酸分子與ｓ１核酸酶於檢測核酸修復酵素活性的用途 |
-
2016
- 2016-04-07 US US15/092,917 patent/US10160987B2/en active Active
-
2017
- 2017-03-24 CA CA2962254A patent/CA2962254C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2962254C (fr) | 2020-07-28 |
| US20170292137A1 (en) | 2017-10-12 |
| US10160987B2 (en) | 2018-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210071171A1 (en) | Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation | |
| EP3234200B1 (fr) | Procédé d'appauvrissement ciblé d'acides nucléiques utilisant les protéines du système cas/crispr | |
| JP4789271B2 (ja) | エラーが最小化された核酸分子の合成 | |
| US20120244525A1 (en) | Oligonucleotide Adapters: Compositions and Methods of Use | |
| EP1451365A2 (fr) | Amplification et sequencage d'adn au moyen de molecules d'adn produite par fragmentation aleatoire | |
| US20230056763A1 (en) | Methods of targeted sequencing | |
| WO2019030306A1 (fr) | Isolement et enrichissement in vitro d'acides nucléiques à l'aide de nucléases spécifiques à un site | |
| CN103687961B (zh) | 用于等温全基因组扩增的方法和组合物 | |
| CN114901818A (zh) | 靶向核酸文库形成的方法 | |
| US20130123117A1 (en) | Capture probe and assay for analysis of fragmented nucleic acids | |
| CA2962254C (fr) | Composition et procede de traitement de l'adn | |
| WO2001029212A1 (fr) | Procede de genese de chimeres de genomes entiers ou de polynucleotides de grande taille | |
| KR20230161955A (ko) | 등온 상보적 dna 및 라이브러리 제조의 개선된 방법 | |
| EP2152901B1 (fr) | Procédé permettant d'introduire des éléments de séquence communs et/ou individuels dans une molécule cible d'acide nucléique | |
| WO2017066592A1 (fr) | Procédés et kits d'extension d'amorce unique hautement multiplex | |
| CN117651767A (zh) | 等温互补dna和文库制备的改进方法 | |
| CN115279918A (zh) | 用于测序的新型核酸模板结构 | |
| CN118355129A (zh) | 捕获crispr核酸内切酶切割产物的方法 | |
| WO2001032932A2 (fr) | Procede d"identification d"une sequence d"acide nucleique |